UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 9, 2006
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact name of Registrant as specified in its charter)
Delaware 0-26224 51-0317849
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation or organization) Identification No.)
311 Enterprise Drive
Plainsboro, NJ 08536
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (609) 275-0500
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF PRINCIPAL OFFICERS; COMPENSATION ARRANGEMENT OF CERTAIN OFFICERS.
(b)(c) On November 9, 2006, Jerry E. Corbin replaced David B. Holtz as the
principal accounting officer of Integra LifeSciences Holdings Corporation (the
"Company"). In addition, David Holtz notified the Company that he will be
leaving the Company at the end of the year to pursue other opportunities. Mr.
Holtz's last day with the Company will be December 31, 2006.
Mr. Corbin joined the Company as Vice President and Corporate Controller in June
2006. From 1989 to 2006, Mr. Corbin held key finance positions in corporate
accounting, sales and marketing and, most recently, research and development for
sanofi-aventis and its predecessors. Prior to that, he held management positions
with Sigma-Aldrich Corporation and Edward D. Jones & Company. Mr. Corbin is 46
years old.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
Exhibit Number Description of Exhibit
- -------------- ---------------------------
99.1 Press release issued November 9, 2006
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
INTEGRA LIFESCIENCES HOLDINGS
CORPORATION
Date: November 14, 2006 By: /s/ Stuart M. Essig
-----------------------------
Stuart M. Essig
President and Chief Executive Officer
Exhibit Index
Exhibit Number Description of Exhibit
- -------------- ---------------------------
99.1 Press release issued November 9, 2006
News Release
Contacts:
Integra LifeSciences Holdings Corporation
Maureen B. Bellantoni John Bostjancic
Executive Vice President Vice President, Corporate Development
and Chief Financial Officer and Investor Relations
(609) 936-6822 (609) 936-2239
maureen.bellantoni@Integra-LS.com jbostjancic@Integra-LS.com
Integra LifeSciences Names Jerry Corbin to Role of
Principal Accounting Officer
Plainsboro, New Jersey / November 9, 2006 / -- Integra LifeSciences Holdings
Corporation (NASDAQ: IART) announced today that Jerry E. Corbin has been named
principal accounting officer, replacing David B. Holtz in that role. Mr. Corbin
joined the company earlier this year as Vice President, Corporate Controller. In
addition, David Holtz, Integra's Senior Vice President, Finance, has notified
Integra that he will be leaving Integra at the end of the year to pursue other
opportunities.
"Jerry Corbin has made significant contributions since joining Integra," said
Maureen B. Bellantoni, Integra's Chief Financial Officer. "Jerry's added role of
Principal Accounting Officer is recognition of these contributions as well as
the importance his position holds to Integra, the Board, and our entire
organization."
"I am pleased to be part of the Integra team," said Mr. Corbin. "As Principal
Accounting Officer, I will continue Integra's commitment to reporting and
complying with SEC and GAAP regulations, and promoting sound accounting and
control practices throughout our company. I am enthusiastic about contributing
to Integra's mission of becoming a leader in medical devices used in
neurosurgery, reconstructive surgery and general surgery. I believe Integra is
financially well positioned as it continues to pursue its growth strategy."
Stuart M. Essig, Integra's Chief Executive Officer, added, "David Holtz has
played a critical role at Integra. He oversaw the accounting and financial
planning functions at Integra for over 12 years with strong and steady
leadership, followed by his assuming responsibility for Integra's worldwide
shared services and planning earlier this year. On behalf of everyone at
Integra, we wish David the very best. And, we thank him for his many
contributions to Integra during his tenure with us."
Mr. Corbin joined Integra as Vice President and Corporate Controller in June
2006. From 1989 to 2006, Mr. Corbin held key finance positions in corporate
accounting, sales and marketing and, most recently, research and development for
sanofi-aventis and its predecessors. Prior to that, he held management positions
with Sigma-Aldrich Corporation and Edward D. Jones & Company. Mr. Corbin holds a
BS in Accounting from Illinois State University and is a certified public
accountant.
Integra LifeSciences Holdings Corporation is a diversified medical technology
company. We develop, manufacture, and market medical devices for use in a
variety of applications. The primary applications for our products are
neurosurgery, reconstructive surgery and general surgery. Integra is a leader in
applying the principles of biotechnology to medical devices that improve
patients' quality of life. Our corporate headquarters are in Plainsboro, New
Jersey. We have research, manufacturing and distribution facilities throughout
the world. Please visit our website at (http://www.Integra-LS.com).
Source: Integra LifeSciences Holdings Corporation